pipette
ESEspañol

Germline homologous recombination deficiency influences TP53-mutant clonal hematopoiesis fitness during platinum and PARP inhibitor treatment

Jeremy T. Baeten, Irenaeus C.C. Chan, Lea Moukarzel, Giulia E.M. Petrone, Jie Liu, Duc Tran, Jacob Tabs, Imène Tabet, Sumedha Agashe, Elaheh Nasrollahzadeh, Ankush Vasireddy, Amber Carter, Minal Patel, Konrad Hermann Stopsack, Philip W. Kantoff, Weiyin Zhou, Armel Landry Batchi-Bouyou, J. Scott Beeler, Griffen Mustion, Paul D.P. Pharoah, James D. Brenton, Kenneth Offit, Ethan Barnett, Bob T. Li, Wassim Abida, Alison M. Schram, Britta Weigelt, David G. Mutch, Alessandro Vindigni, Mary Mullen, Carlos C Cruchaga, Howard I. Scher, Ross L. Levine, Elli Papaemmanuil, Mitchell J. Machiela, Karen Cadoo, Daniel C. Link, Kelly L. Bolton

Peer-reviewed journalReal-world use

In the authors' words

Poly(ADP-ribose) polymerase inhibitors (PARPi) are commonly used in tumors with homologous recombination deficiency (HRD) but are associated with an increased risk of therapy-related myeloid neoplasms (tMN). Clonal hematopoiesis (CH) driven by DNA damage response (DDR) mutations is the origin of most tMN. Here, to better understand the causes of tMN following PARPi therapy, we studied the relationship between PARPi use and CH. We observed a high frequency of DDR CH following PARPi therapy, largely explained by prior carboplatin exposure. Among patients with serial blood sampling, DDR CH expanded during carboplatin and to a lesser extent, during PARPi treatment. Surprisingly, this expansion was largely reduced in patients with germline HRD. We validated these findings in a mouse model of Trp53-mutated CH. Our findings suggest that the increased risk of tMN following PARPi is largely influenced by prior oncologic therapies, including carboplatin, and may vary by germline HRD status. The authors show that platinum is a greater driver of DNA damage response gene-mutant clonal hematopoiesis than poly(ADP-ribose) polymerase inhibitors and that the presence of germline mutations conferring homologous recombination deficiency reduces the rate of expansion of these clones.

Main resultThe abstract does not state a limitation.

Appeared: Wednesday, September 30. Nature Genetics. Peer-reviewed journal.

DOI: 10.1038/s41588-026-02752-2